

Update of EULAR recommendations for the treatment of

Annals of the Rheumatic Diseases

76, 1327-1339

DOI: 10.1136/annrheumdis-2016-209909

Citation Report

#	ARTICLE	IF	CITATIONS
2	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2016, 315, 1975.	7.4	95
3	What should clinicians know about the use of glucocorticoids in systemic sclerosis?. Modern Rheumatology, 2017, 27, 919-923.	1.8	10
4	Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Review of Clinical Immunology, 2017, 13, 469-482.	3.0	29
5	Fluoxetine and Raynaud's phenomenon: friend or foe?. British Journal of Clinical Pharmacology, 2017, 83, 2307-2309.	2.4	7
6	Non-healing ischaemic digital ulcer in a systemic sclerosis patient: a challenging clinical case. International Wound Journal, 2017, 14, 978-981.	2.9	4
7	Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. Seminars in Arthritis and Rheumatism, 2017, 46, 767-774.	3.4	32
8	Reflections on the EULAR recommendations for the treatment of systemic sclerosis. Nature Reviews Rheumatology, 2017, 13, 134-136.	8.0	3
9	Rituximab Experience in Patients With Long-standing Systemic Sclerosis-Associated Interstitial Lung Disease. Journal of Clinical Rheumatology, 2017, 23, 411-415.	0.9	33
10	Evidence-based management of Raynaud's phenomenon. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 317-329.	2.7	21
11	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 2370-2379.	5.6	49
12	Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Research and Therapy, 2017, 19, 145.	3.5	39
13	Pulmonary arterial hypertension in scleroderma: care gaps in screening. Arthritis Research and Therapy, 2017, 19, 128.	3.5	3
15	Scleroderma in children. Best Practice and Research in Clinical Rheumatology, 2017, 31, 576-595.	3.3	37
16	Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. Journal of Scleroderma and Related Disorders, 2017, 2, S29-S35.	1.7	10
17	Systemic sclerosis "diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring. Przegląd Dermatologiczny, 2017, 5, 483-498.	0.1	9
18	Increased Whole Blood Viscosity Is Associated with the Presence of Digital Ulcers in Systemic Sclerosis: Results from a Cross-Sectional Pilot Study. Autoimmune Diseases, 2017, 2017, 1-5.	0.6	7
19	Systemic sclerosis "diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: treatment. Przegląd Dermatologiczny, 2017, 104, 583-596.	0.1	4
20	Controversies on the Use of Steroids in Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 84-91.	1.7	13

#	ARTICLE	IF	CITATIONS
21	Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease. <i>Rheumatology International</i> , 2018, 38, 813-819.	3.0	29
22	Intestinal Involvement in Systemic Sclerosis: A Clinical Review. <i>Digestive Diseases and Sciences</i> , 2018, 63, 834-844.	2.3	44
23	Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives. <i>Rheumatology International</i> , 2018, 38, 949-958.	3.0	20
24	The role of the dermatologist in Raynaud's phenomenon: a clinical challenge. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1120-1127.	2.4	10
26	A 22-Year-Old Woman With Systemic Lupus Erythematosus Presents With Two Damaged Kidneys, One Seizure, No Platelets, and Many Possible Diagnoses. <i>Arthritis Care and Research</i> , 2018, 70, 1686-1693.	3.4	1
27	The challenge of establishing treatment efficacy for cutaneous vascular manifestations of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 431-442.	3.0	12
28	Systemic sclerosis: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , 2018, 36, 459-474.	1.6	43
30	Scleroderma-like renal crisis in a patient with anti-threonyl-tRNA synthetase-associated antisynthetase syndrome. <i>Rheumatology</i> , 2018, 57, 763-765.	1.9	5
31	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 813-817.	1.9	21
32	Systemic sclerosis: clinical features and management. <i>Medicine</i> , 2018, 46, 131-139.	0.4	3
33	Changes in macrophage transcriptome associate with systemic sclerosis and mediate <i>GSDMA</i> contribution to disease risk. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 596-601.	0.9	60
34	Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a pragmatic non-randomized trial. <i>Rheumatology</i> , 2018, 57, 1408-1416.	1.9	13
35	Avancées thérapeutiques dans l'atteinte interstitielle pulmonaire au cours de la sclérodermie systémique. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 165-170.	0.0	1
36	Agonistic antibodies in systemic sclerosis. <i>Immunology Letters</i> , 2018, 195, 83-87.	2.5	22
37	Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. <i>Autoimmunity Reviews</i> , 2018, 17, 155-164.	5.8	49
38	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 69-82.	3.0	64
39	Autologous hematopoietic stem cell transplantation in systemic sclerosis: A reset to tolerance?. <i>Immunology Letters</i> , 2018, 195, 88-96.	2.5	12
40	Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 563-571.	3.3	24

#	ARTICLE	IF	CITATIONS
41	Trends in incidence, mortality, and causes of death associated with systemic sclerosis in Denmark between 1995 and 2015: a nationwide cohort study. BMC Rheumatology, 2018, 2, 36.	1.6	31
42	Raynaud's Phenomenon. , 2018, , .		0
43	What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study. Rheumatology Advances in Practice, 2018, 2, rky027.	0.7	6
44	Cellular networks in wound healing. Science, 2018, 362, 891-892.	12.6	44
45	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences, 2018, 19, 3528.	4.1	143
46	Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management. Reumatologia, 2018, 56, 249-254.	1.1	23
47	Hematopoietic stem-cell transplantation in systemic sclerosis: an update. Current Opinion in Rheumatology, 2018, 30, 541-547.	4.3	14
48	Gastrointestinal involvement in systemic sclerosis: diagnosis and management. Current Opinion in Rheumatology, 2018, 30, 533-540.	4.3	20
49	Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 2390.	4.8	42
50	Connective Tissue Related Interstitial Lung Disease. Current Pulmonology Reports, 2018, 7, 133-148.	1.3	0
51	On-Demand Sildenafil as a Treatment for Raynaud Phenomenon. Annals of Internal Medicine, 2018, 169, 694.	3.9	26
53	Clinical pattern of systemic sclerosis in Central Ukraine. Association between clinical manifestations of systemic sclerosis and hypertension. Reumatologia, 2018, 56, 24-30.	1.1	3
54	Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis and Rheumatology, 2018, 70, 1820-1828.	5.6	185
55	Systemic sclerosis phase III clinical trials: Hope on the horizon?. Journal of Scleroderma and Related Disorders, 2018, 3, 193-200.	1.7	5
56	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1961-1964.	2.0	47
57	Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology, 2018, 57, 1802-1811.	1.9	46
58	Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms. Journal of Autoimmunity, 2018, 92, 35-46.	6.5	51
59	New treatment paradigms for connective tissue disease-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 453-460.	2.6	10

#	ARTICLE	IF	CITATIONS
60	A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis. BMC Rheumatology, 2018, 2, 13.	1.6	1
61	Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE, 2018, 13, e0196048.	2.5	34
62	Haematopoietic stem cell transplantation in systemic sclerosis. RMD Open, 2018, 4, e000533.	3.8	31
63	IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis. Frontiers in Immunology, 2018, 9, 1611.	4.8	69
64	Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist. Clinical Medicine, 2018, 18, 329-334.	1.9	34
65	Resetting the T Cell Compartment in Autoimmune Diseases With Autologous Hematopoietic Stem Cell Transplantation: An Update. Frontiers in Immunology, 2018, 9, 767.	4.8	13
66	Pharmacotherapy Options in the Management of Raynaud’s Phenomenon. Current Treatment Options in Rheumatology, 2018, 4, 235-254.	1.4	12
67	Essential and Optional Drugs for Rheumatic Diseases. Handbook of Systemic Autoimmune Diseases, 2018, , 77-96.	0.1	0
68	Review of local wound management for scleroderma-associated digital ulcers. Journal of Scleroderma and Related Disorders, 2018, 3, 66-70.	1.7	17
69	Therapy of scleroderma renal crisis: State of the art. Autoimmunity Reviews, 2018, 17, 882-889.	5.8	53
70	Scleroderma in Children and Adolescents. Pediatric Clinics of North America, 2018, 65, 757-781.	1.8	64
71	Rheumatology science and practice in India. Rheumatology International, 2018, 38, 1587-1600.	3.0	18
72	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. Arthritis Research and Therapy, 2018, 20, 17.	3.5	75
73	Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist’s, Clinician’s, and Patient’s Perspective. Clinical Reviews in Allergy and Immunology, 2018, 55, 312-331.	6.5	15
74	Kidney involvement in systemic sclerosis: From pathogenesis to treatment. Journal of Scleroderma and Related Disorders, 2018, 3, 43-52.	1.7	32
75	How do patients with systemic autoimmune rheumatic disease perceive the use of their medications: a systematic review and thematic synthesis of qualitative research. BMC Rheumatology, 2018, 2, 9.	1.6	8
77	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials, 2018, 19, 449.	1.6	14
78	Major lung complications of systemic sclerosis. Nature Reviews Rheumatology, 2018, 14, 511-527.	8.0	60

#	ARTICLE	IF	CITATIONS
79	The contemporary management of systemic sclerosis. Expert Review of Clinical Immunology, 2018, 14, 573-582.	3.0	2
80	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Annals of the Rheumatic Diseases, 2018, 77, 1326-1332.	0.9	100
81	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology, 2019, 58, 567-579.	1.9	51
82	Increased risk of mortality in systemic sclerosis-associated digital ulcers: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 405-409.	2.4	12
83	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	2.2	38
85	Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. Journal of Controlled Release, 2019, 310, 198-208.	9.9	36
87	Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs, 2019, 79, 1511-1528.	10.9	35
88	The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. Expert Review of Clinical Immunology, 2019, 15, 981-985.	3.0	17
89	Raynaud's phenomenon—an update on diagnosis, classification and management. Clinical Rheumatology, 2019, 38, 3317-3330.	2.2	67
90	Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis. Rheumatology International, 2019, 39, 1841-1848.	3.0	8
91	Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. Clinics in Chest Medicine, 2019, 40, 501-518.	2.1	32
92	Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Review of Current Status. BioDrugs, 2019, 33, 401-409.	4.6	9
93	Preserving Pulmonary Function: A Palliative Intervention. Journal for Nurse Practitioners, 2019, 15, 579-582.	0.8	1
94	Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1258-1266.	5.6	146
95	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Current Medical Research and Opinion, 2019, 35, 2015-2024.	1.9	148
96	Systemic sclerosis – the dermatological perspective. JDDG - Journal of the German Society of Dermatology, 2019, 17, 716-728.	0.8	8
97	Targeting very early systemic sclerosis: a case-based review. Rheumatology International, 2019, 39, 1961-1970.	3.0	15
98	Serum concentration of beta-trace protein (BTP) as a potential biomarker of systemic sclerosis. Przegląd Dermatologiczny, 2019, 106, 173-184.	0.1	0

#	ARTICLE	IF	CITATIONS
99	Rheopheresis for Digital Ulcers and Raynaud's Phenomenon in Systemic Sclerosis Refractory to Conventional Treatments. <i>Frontiers in Medicine</i> , 2019, 6, 208.	2.6	7
100	Digital ulcers in systemic sclerosis and insulin-dependent diabetes mellitus type 2. <i>Rheumatology Advances in Practice</i> , 2019, 3, rz019.	0.7	0
103	Endothelin: 30 Years From Discovery to Therapy. <i>Hypertension</i> , 2019, 74, 1232-1265.	2.7	153
104	Is there today a place for corticosteroids in the treatment of scleroderma?. <i>Autoimmunity Reviews</i> , 2019, 18, 102403.	5.8	18
105	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2019, 46, 1006-1013.	1.2	47
106	Systemische Sklerodermie – die dermatologische Sicht. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 716-729.	0.8	3
107	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , 2019, 21, 202.	3.5	21
108	Systemic sclerosis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 530-536.	0.5	75
109	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1009-1017.	3.0	42
110	Systemic sclerosis – multidisciplinary disease: clinical features and treatment. <i>Reumatologia</i> , 2019, 57, 221-233.	1.1	82
111	Scleroderma-related interstitial lung disease: principles of management. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 357-367.	2.5	7
112	Management of Raynaud's phenomenon in systemic sclerosis – a practical approach. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 102-110.	1.7	9
113	CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan. <i>Arthritis Research and Therapy</i> , 2019, 21, 30.	3.5	22
114	Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors. <i>Frontiers in Immunology</i> , 2018, 9, 3112.	4.8	62
116	Interstitial lung disease associated with systemic sclerosis (SSc-ILD). <i>Respiratory Research</i> , 2019, 20, 13.	3.6	160
117	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2019, 54, 933-942.	2.4	25
119	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 2273-2283.	1.9	22
120	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. <i>Journal of Clinical Apheresis</i> , 2019, 34, 171-354.	1.3	1,263

#	ARTICLE	IF	CITATIONS
121	<p>Management of digital ulcers in systemic sclerosis</p>. Chronic Wound Care Management and Research, 0, Volume 6, 9-18.	0.4	6
122	Gaining the Upper Hand on Systemic Sclerosis Digital Ulcers. Journal of Rheumatology, 2019, 46, 548-549.	2.0	1
123	Is There a Place for Hematopoietic Stem Cell Transplantation in Rheumatology?. Rheumatic Disease Clinics of North America, 2019, 45, 399-416.	1.9	6
124	Management of Fibrosing Interstitial Lung Diseases. Advances in Therapy, 2019, 36, 1518-1531.	2.9	27
125	<p>Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease</p>. Clinical Epidemiology, 2019, Volume 11, 257-273.	3.0	138
127	Innovations in the Assessment of Primary and Secondary Raynaud’s Phenomenon. Frontiers in Pharmacology, 2019, 10, 360.	3.5	40
128	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. RMD Open, 2019, 5, e000826.	3.8	35
129	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis’s associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2019, 4, 212-218.	1.7	31
130	Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clinical and Experimental Medicine, 2019, 19, 357-366.	3.6	23
131	Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis. Current Treatment Options in Rheumatology, 2019, 5, 115-126.	1.4	1
132	Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study. Frontiers in Pharmacology, 2019, 10, 293.	3.5	10
133	Distal radius and tibia bone microarchitecture impairment in female patients with diffuse systemic sclerosis. Osteoporosis International, 2019, 30, 1679-1691.	3.1	5
134	Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis?. Current Rheumatology Reports, 2019, 21, 15.	4.7	26
135	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. Current Treatment Options in Rheumatology, 2019, 5, 85-103.	1.4	8
136	Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis – a cross-sectional study. Biomarkers, 2019, 24, 373-378.	1.9	11
137	Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review, 2019, 28, 180100.	7.1	191
138	Autologous hematopoietic stem cell transplant for progressive diffuse systemic sclerosis: procedural success and clinical outcome in 5-year follow-up. Reumatologia, 2019, 57, 50-54.	1.1	5
139	Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis. Current Treatment Options in Rheumatology, 2019, 5, 127-146.	1.4	0



#	ARTICLE	IF	CITATIONS
140	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
141	Correlations between nailfold microvascular damage and skin involvement in systemic sclerosis patients. Microvascular Research, 2019, 125, 103874.	2.5	19
142	Rheumatology in Poland. Rheumatology International, 2019, 39, 757-767.	3.0	8
143	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
144	Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. Nature Reviews Rheumatology, 2019, 15, 288-302.	8.0	48
145	Emerging targets of disease-modifying therapy for systemic sclerosis. Nature Reviews Rheumatology, 2019, 15, 208-224.	8.0	91
146	Impact of Therapeutic Angiogenesis Using Autologous Bone Marrow-Derived Mononuclear Cells Implantation in Critical Limb Ischemia With Sclerodermaâ€• Subanalysis of the Long-Term Clinical Outcomes Survey â€•. Circulation Journal, 2019, 83, 662-671.	1.6	6
147	Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. BioMed Research International, 2019, 2019, 1-15.	1.9	55
148	Second autologous haematopoietic stem cell transplantation in systemic sclerosisâ€•a case report. Rheumatology, 2019, 58, 1305-1307.	1.9	2
149	Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review. Annals of the Rheumatic Diseases, 2019, 78, 562-569.	0.9	17
150	Raynaudâ€™s phenomenon. Journal of Scleroderma and Related Disorders, 2019, 4, 89-101.	1.7	18
151	Myeloid disorders after autoimmune disease. Best Practice and Research in Clinical Haematology, 2019, 32, 74-88.	1.7	19
152	Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000782.	3.8	91
153	AB0655â€•...SCLERONETÂ®: A PATIENT-CENTERED MULTIDISCIPLINARY APPROACH TO SYSTEMIC SCLEROSIS. , 2019, ,		0
155	Autologous hematopoietic stem cell transplantation in autoimmune diseases â€• a brand new standard. Where do we go from here?. Reumatologia, 2019, 57, 307-308.	1.1	0
156	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. Annals of the Rheumatic Diseases, 2019, 78, 1681-1685.	0.9	13
157	Endotypeâ€•phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine, 2019, 50, 379-386.	6.1	41
159	The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder. Lancet Rheumatology, The, 2019, 1, e257-e264.	3.9	17

#	ARTICLE	IF	CITATIONS
160	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e237-e246.	3.9	18
161	Gastrointestinal Involvement in Systemic Sclerosis: Overview, Neglected Aspects, Malnutrition, Body Composition and Management. , 0, , .		0
162	Rituximab in systemic sclerosis. <i>Medicine (United States)</i> , 2019, 98, e17110.	1.0	7
163	Application of stem cell transplantation in autoimmune diseases. <i>Current Opinion in Hematology</i> , 2019, 26, 392-398.	2.5	12
164	Systemic sclerosis. , 2019, , 291-329.		0
165	Raynaud's phenomenon: no net effects of vasodilators in a network analysis. <i>Lancet Rheumatology</i> , The, 2019, 1, e200-e202.	3.9	0
166	Management of scleroderma renal crisis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 223-230.	4.3	26
167	Gastrointestinal Manifestations of Rheumatological Diseases. <i>American Journal of Gastroenterology</i> , 2019, 114, 1441-1454.	0.4	38
168	Scleroderma Renal Crisis Complicated with Thrombotic Microangiopathy Triggered by Influenza B Virus Infection. <i>Internal Medicine</i> , 2019, 58, 441-445.	0.7	11
169	Haematopoietic stem cell transplants: principles and indications. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 33-39.	0.5	59
170	Scleroderma Renal Crisis: Still a Lot To Do. <i>Journal of Rheumatology</i> , 2019, 46, 3-4.	2.0	2
171	Wound Dressing for Digital Ulcers in Systemic Sclerosis. , 2019, , 161-164.		0
172	Ulcer Healing and Prevention in Systemic Sclerosis. , 2019, , 167-171.		1
173	Bulgarian rheumatology: science and practice in a cost-constrained environment. <i>Rheumatology International</i> , 2019, 39, 417-429.	3.0	11
174	Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 149-159.	1.7	5
175	Perspectives on the interlinked nature of systemic sclerosis and reflux disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 213-227.	3.0	9
176	Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 391-398.	0.9	29
177	Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. <i>Acta Clinica Belgica</i> , 2019, 74, 272-279.	1.2	31

#	ARTICLE	IF	CITATIONS
178	Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides. <i>Rheumatology</i> , 2019, 58, 313-320.	1.9	36
179	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 18-26.	1.9	37
180	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 686-693.	3.4	34
181	Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSSciphier study. <i>Clinical Rheumatology</i> , 2020, 39, 27-36.	2.2	18
182	Large Variability of Frequency and Type of Physical Therapy in Patients in the German Network for Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 1041-1048.	3.4	3
183	Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 135-139.	3.4	12
184	Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2020, 47, 249-254.	2.0	23
185	Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1108-1117.	1.9	12
186	Health-related quality of life in systemic sclerosis before and after autologous haematopoietic stem cell transplant—a systematic review. <i>Rheumatology</i> , 2020, 59, 779-789.	1.9	16
187	Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 317-325.	1.2	52
188	Systemic sclerosis: Recent insight in clinical management. <i>Joint Bone Spine</i> , 2020, 87, 293-299.	1.6	31
189	Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 159-164.	1.7	2
190	El método Delphi en la investigación en reumatología: ¿lo estamos haciendo bien?. <i>Revista Colombiana De Reumatología</i> , 2020, 27, 177-189.	0.1	5
191	Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. <i>Cytokine</i> , 2020, 125, 154799.	3.2	43
192	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
193	Small intestinal bacterial overgrowth in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 33-39.	1.7	4
194	Absolute Rheumatology Review. , 2020, , .		1
195	Lung disease related to connective tissue diseases. , 2020, , 265-319.		0

#	ARTICLE	IF	CITATIONS
196	Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target?. <i>Rheumatology</i> , 2020, 59, 464-466.	1.9	14
197	The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. <i>Rheumatology</i> , 2020, 59, 1407-1415.	1.9	22
198	Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?. <i>Cells</i> , 2020, 9, 77.	4.1	16
200	Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population. <i>Rheumatology and Therapy</i> , 2020, 7, 89-99.	2.3	10
201	Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. <i>Rheumatology</i> , 2020, 59, 1051-1058.	1.9	27
202	Vitamin D and Cytokine Profiles in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 289-294.	0.9	11
203	Limited cutaneous systemic sclerosis with gangrene: an autopsy case. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 243-247.	0.7	1
204	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. <i>Rheumatology</i> , 2020, 59, 2052-2061.	1.9	13
206	Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. <i>Modern Rheumatology</i> , 2020, 30, 225-231.	1.8	29
208	Patient-reported outcome instruments in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 90-102.	1.7	14
209	Automatic Quantitative Computed Tomography Evaluation of the Lungs in Patients With Systemic Sclerosis Treated With Autologous Stem Cell Transplantation. <i>Journal of Clinical Rheumatology</i> , 2020, 26, S158-S164.	0.9	8
210	From Head to Toe. <i>Journal of Clinical Rheumatology</i> , 2020, 26, e297-e297.	0.9	0
211	Detection, screening, and classification of interstitial lung disease in patients with systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 497-504.	4.3	15
212	Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). <i>Frontiers in Immunology</i> , 2020, 11, 1990.	4.8	9
213	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 455-466.	2.4	7
214	Clinical Efficacy and Safety of Injection of Stromal Vascular Fraction Derived from Autologous Adipose Tissues in Systemic Sclerosis Patients with Hand Disability: A Proof-Of-Concept Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3023.	2.4	15
215	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
216	Endothelial dysfunction in patients with systemic sclerosis. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 495-502.	0.9	11

#	ARTICLE	IF	CITATIONS
217	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. Autoimmunity Reviews, 2020, 19, 102659.	5.8	14
218	Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Review of Clinical Pharmacology, 2020, 13, 1203-1218.	3.1	4
219	An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 2041-2056.	1.8	15
220	Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus. IJU Case Reports, 2020, 3, 181-183.	0.3	2
222	Hematological Manifestations among Patients with Rheumatic Diseases. Acta Haematologica, 2021, 144, 403-412.	1.4	21
224	Immunomodulation in Autoimmune Interstitial Lung Disease. Respiration, 2020, 99, 819-829.	2.6	4
225	Atherosclerosis in Rheumatology: Old and New Insights. , 0, , .		0
226	Systemic Sclerosis. , 2020, , .		0
227	Elevated Circulatory Levels of Microparticles Are Associated to Lung Fibrosis and Vasculopathy During Systemic Sclerosis. Frontiers in Immunology, 2020, 11, 532177.	4.8	13
228	Frailty in Rheumatic Diseases. Frontiers in Immunology, 2020, 11, 576134.	4.8	40
229	Pulmonary mucormycosis following autologous hematopoietic stem cell transplantation for rapidly progressive diffuse cutaneous systemic sclerosis. Medicine (United States), 2020, 99, e21431.	1.0	1
230	Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Seminars in Arthritis and Rheumatism, 2020, 50, 977-987.	3.4	16
231	Systemic sclerosis-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2020, 26, 487-495.	2.6	3
232	The role of the renin-angiotensin system in skin physiology and pathophysiology. Experimental Dermatology, 2020, 29, 891-901.	2.9	27
233	Superior Mesenteric Artery Syndrome: A Potentially Fatal but Reversible Gastrointestinal Manifestation of Systemic Sclerosis. Case Reports in Rheumatology, 2020, 2020, 1-6.	0.6	2
234	The need for a holistic approach for SSc-ILD “achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	3.6	33
235	Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2560.	2.4	16
236	Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation. Arthritis Research and Therapy, 2020, 22, 183.	3.5	11

#	ARTICLE	IF	CITATIONS
237	High NEMO score values in nailfold videocapillaroscopy are associated with the subsequent development of ischaemic digital ulcers in patients with systemic sclerosis. Arthritis Research and Therapy, 2020, 22, 237.	3.5	4
238	Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis. Frontiers in Immunology, 2020, 11, 582401.	4.8	34
239	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. Expert Review of Clinical Immunology, 2020, 16, 1065-1074.	3.0	5
240	A Real-World Experience of Mycophenolate Mofetil for Systemic Sclerosis: A Retrospective Multicenter Observational Study. Archives of Rheumatology, 2020, 35, 366-375.	0.9	4
241	Mesenchymal stromal cells represent a therapeutic option for systemic sclerosis patients. Revista Colombiana De Reumatología (English Edition), 2020, 27, 126-134.	0.0	0
242	Systemic sclerosis and gastrointestinal involvement. Revista Colombiana De Reumatología (English) Tj ETQq1 1 0.784314 rgBT /Overlo	0.0	3
243	Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint). Experimental Dermatology, 2020, 29, 1144-1153.	2.9	8
244	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. Arthritis Care and Research, 2020, , .	3.4	13
245	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. Expert Review of Clinical Immunology, 2020, 16, 993-1004.	3.0	7
246	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
247	Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. Autoimmunity Reviews, 2020, 19, 102662.	5.8	5
248	Tolerance-inducing medicines in autoimmunity: rheumatology and beyond. Lancet Rheumatology, The, 2020, 2, e565-e575.	3.9	10
249	Pericarditis in Systemic Rheumatologic Diseases. Current Cardiology Reports, 2020, 22, 142.	2.9	22
250	Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Expert Review of Clinical Immunology, 2020, 16, 931-942.	3.0	5
251	Infections and systemic sclerosis: an emerging challenge. Revista Colombiana De Reumatología (English Edition), 2020, 27, 62-84.	0.0	1
252	CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases. Biomedicines, 2020, 8, 592.	3.2	12
253	Immunosuppressive treatment for systemic sclerosisâ€”Therapeutic challenges during the COVID â€”19 pandemic. Dermatologic Therapy, 2020, 33, e13619.	1.7	2
254	The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. International Journal of Molecular Sciences, 2020, 21, 3531.	4.1	37

#	ARTICLE	IF	CITATIONS
255	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
256	Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis. <i>Wiener Klinische Wochenschrift</i> , 2020, 133, 1070-1075.	1.9	3
257	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1084-1089.	0.9	32
258	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 547-560.	3.0	5
259	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. <i>Autoimmunity Reviews</i> , 2020, 19, 102583.	5.8	25
260	Digit Ulcerations in a Young Woman. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 385.	7.4	0
261	Paraneoplastic Raynaud's phenomenon as sign of progression: a case report on a patient with breast cancer. <i>Acta Clinica Belgica</i> , 2020, , 1-4.	1.2	1
262	The Delphi method in rheumatology research: are we doing it right?. <i>Revista Colombiana De Reumatología (English Edition)</i> , 2020, 27, 177-189.	0.0	2
263	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020, 22, 132.	3.5	5
264	Expert Perspectives On Clinical Challenges: Expert Perspectives: Challenges in Scleroderma. <i>Arthritis and Rheumatology</i> , 2020, 72, 1415-1426.	5.6	0
265	Drugs in phase I and phase II clinical trials for systemic sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 349-362.	4.1	10
266	The "Connective Tissue Diseases", 2020, , 1-64.		0
267	Successful Treatment of Pulmonary Arterial Hypertension in Systemic Sclerosis with Anticentriole Antibody. <i>Case Reports in Rheumatology</i> , 2020, 2020, 1-7.	0.6	0
268	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.7	43
269	Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. <i>Lancet Rheumatology</i> , The, 2020, 2, e173-e184.	3.9	12
270	Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 824.	2.4	64
271	Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 56.	3.5	12
272	Management of systemic sclerosis: the first five years. <i>Current Opinion in Rheumatology</i> , 2020, 32, 228-237.	4.3	38



#	ARTICLE	IF	CITATIONS
273	Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease—a randomised controlled trial. <i>Rheumatology International</i> , 2020, 40, 703-710.	3.0	64
274	Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4430.	4.1	20
275	Treatment in Juvenile Scleroderma. <i>Current Rheumatology Reports</i> , 2020, 22, 45.	4.7	6
276	Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake. <i>Journal of Rheumatology</i> , 2020, 47, 164-165.	2.0	1
277	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 407.	2.4	40
278	Digital ulcers: should debridement be a standard of care in systemic sclerosis?. <i>Lancet Rheumatology</i> , The, 2020, 2, e302-e307.	3.9	7
279	Predictors of progression in systemic sclerosis patients with interstitial lung disease. <i>European Respiratory Journal</i> , 2020, 55, 1902026.	6.7	134
280	Treprostinil Hydrogel Iontophoresis in Systemic Sclerosis-Related Digital Skin Ulcers: A Safety Study. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 758-767.	2.0	13
281	The future of treatment in systemic sclerosis: can we design better trials?. <i>Lancet Rheumatology</i> , The, 2020, 2, e185-e194.	3.9	10
284	Systemic sclerosis-associated interstitial lung disease. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 304-320.	10.7	202
285	Serotonin: A Potent Immune Cell Modulator in Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 186.	4.8	88
286	Chronic inflammatory diseases, myocardial function and cardioprotection. <i>British Journal of Pharmacology</i> , 2020, 177, 5357-5374.	5.4	24
287	Novel insights into dendritic cells in the pathogenesis of systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2020, 201, 25-33.	2.6	26
288	The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. <i>Lancet Rheumatology</i> , The, 2020, 2, e71-e83.	3.9	182
289	Systemic sclerosis: Advances towards stratified medicine. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101469.	3.3	9
290	Consensus statements for managing systemic sclerosis-associated interstitial lung disease. <i>Lancet Rheumatology</i> , The, 2020, 2, e64-e65.	3.9	0
291	Raynaud's phenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101474.	3.3	43
292	Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2217-2222.	2.4	9



#	ARTICLE	IF	CITATIONS
294	Inhibition of effector B cells by ibrutinib in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 66.	3.5	28
295	Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. <i>Integrated Blood Pressure Control</i> , 2020, Volume 13, 15-29.	1.2	24
296	Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis. <i>Advances in Therapy</i> , 2020, 37, 2460-2476.	2.9	10
298	Systemic Sclerosis Sine Scleroderma With Pulmonary Arterial Hypertension in a 3-Year-Old Girl. <i>Pediatrics</i> , 2020, 145, e20192504.	2.1	3
299	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>Annals of Oncology</i> , 2020, 31, 724-744.	1.2	129
300	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSICIS trial. <i>Modern Rheumatology</i> , 2021, 31, 141-150.	1.8	14
301	Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. <i>Haematologica</i> , 2021, 106, 375-383.	3.5	57
302	A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 65-86.	0.2	15
303	Mortality and morbidity in scleroderma renal crisis: A systematic literature review. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 21-36.	1.7	13
304	Consensus-based recommendations for the management of juvenile systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 1651-1658.	1.9	20
305	Economic Burden and Management of Systemic Sclerosis-Associated Interstitial Lung Disease in 8 European Countries: The BUILDup Delphi Consensus Study. <i>Advances in Therapy</i> , 2021, 38, 521-540.	2.9	9
306	Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study. <i>Rheumatology</i> , 2021, 60, 1915-1925.	1.9	15
307	Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 87-95.	1.7	1
308	Antisynthetase syndrome and pulmonary hypertension: report of two cases and review of the literature. <i>Modern Rheumatology Case Reports</i> , 2021, 5, 152-155.	0.7	7
309	The importance of skin manifestations, serology and nailfold (video)capillaroscopy in morphea and systemic sclerosis: current understanding and new insights. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 597-606.	2.4	1
310	Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. <i>Arthritis and Rheumatology</i> , 2021, 73, 520-529.	5.6	21
311	Données récentes sur la prise en charge clinique de la sclérodémie systémique. <i>Revue Du Rhumatisme (Edition Française)</i> , 2021, 88, 24-31.	0.0	0
312	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.9	160

#	ARTICLE	IF	CITATIONS
313	Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). Journal of Scleroderma and Related Disorders, 2021, 6, 146-153.	1.7	4
314	Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?. Journal of Scleroderma and Related Disorders, 2021, 6, 117-122.	1.7	6
315	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. Rheumatology, 2021, 60, 2472-2477.	1.9	20
316	Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology, 2021, 60, 489-491.	1.9	11
317	Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. Respiriology, 2021, 26, 23-51.	2.3	45
318	Systemic Sclerosis: A Comprehensive Approach to Diagnosis and Management. Physician Assistant Clinics, 2021, 6, 159-175.	0.1	0
319	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. Rheumatology, 2021, 60, e129-e131.	1.9	0
320	Pulmonary Manifestations of Rheumatic Diseases in Children. Pediatric Clinics of North America, 2021, 68, 147-166.	1.8	3
321	Review of indications for immunoglobulin (IG) use: Narrowing the gap between supply and demand. Transfusion Clinique Et Biologique, 2021, 28, 96-122.	0.4	26
322	Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annual Review of Medicine, 2021, 72, 215-228.	12.2	44
323	Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study. Rheumatology International, 2021, 41, 121-128.	3.0	11
325	Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders. Clinical Rheumatology, 2021, 40, 2457-2465.	2.2	4
326	A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis. Ocular Immunology and Inflammation, 2021, 29, 81-89.	1.8	21
329	Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110351.	2.7	8
330	Clinical assessment of cardiac impairment favored by two-dimensional speckle tracking echocardiography in patients with systemic sclerosis. Rheumatology, 2022, 61, 2432-2440.	1.9	4
331	Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases. Drugs in Context, 2021, 10, 1-9.	2.2	0
332	Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2022, 62, 273-291.	6.5	28
333	Systemic Sclerosis. , 2021, , 129-141.		0

#	ARTICLE	IF	CITATIONS
334	Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110397.	2.6	11
335	Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications. <i>Archives of Dermatological Research</i> , 2021, 313, 783-791.	1.9	4
336	Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. <i>ERJ Open Research</i> , 2021, 7, 00235-2020.	2.6	11
337	Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. <i>Drugs in Context</i> , 2021, 10, 1-12.	2.2	10
338	Immunomodulation bei autoimmunen interstitiellen Lungenerkrankungen. <i>Karger Kompass Autoimmun</i> , 2021, 3, 2-9.	0.0	0
339	Role of circulating endothelial cells in assessing the severity of systemic sclerosis and predicting its clinical worsening. <i>Scientific Reports</i> , 2021, 11, 2681.	3.3	8
340	Long-term evaluation of autologous hematopoietic stem cell transplantation in a patient with progressive systemic sclerosis. <i>Archives of Rheumatology</i> , 2021, 36, 308-310.	0.9	1
341	Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series. <i>Open Respiratory Archives</i> , 2021, 3, 100080.	0.1	3
342	Sklerodermie bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-21.	0.0	0
343	Locoregional Treatments for Digital Ulcers in Systemic Sclerosis: A Systematic Review. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00478.	1.3	6
344	Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2021, 40, 3039-3051.	2.2	17
345	A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 5814-5819.	1.9	5
346	Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience. <i>Advances in Rheumatology</i> , 2021, 61, 9.	1.7	22
347	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. <i>Rheumatology</i> , 2021, 60, 5601-5609.	1.9	10
348	Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina. <i>Reumatología Clínica</i> , 2021, , .	0.5	0
349	Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 66-72.	0.5	1
350	Effect of shortâ€interval rituximab and highâ€dose corticosteroids on kidney function in systemic sclerosis: Longâ€term experience of a single centre. <i>International Journal of Clinical Practice</i> , 2021, 75, e14069.	1.7	3
351	Prostanoids in scleroderma microangiopathy: clinical and pharmacoeconomic comparison between two intravenous regimens. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 307-313.	1.1	6

#	ARTICLE	IF	CITATIONS
352	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). Orphanet Journal of Rare Diseases, 2021, 16, 90.	2.7	9
353	Use of calcium channel blockers in dermatology: a narrative review. Expert Review of Clinical Pharmacology, 2021, 14, 481-489.	3.1	5
354	Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Advances in Rheumatology, 2021, 61, 15.	1.7	17
355	The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals, 2021, 14, 154.	3.8	13
356	Interstitial lung disease in systemic sclerosis (systemic scleroderma). Sovremennaya Revmatologiya, 2021, 15, 1-62.	0.5	2
357	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open, 2021, 11, e044483.	1.9	11
358	Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. ACR Open Rheumatology, 2021, 3, 295-304.	2.1	9
359	Natural variability in the disease course of SSc-ILD: implications for treatment. European Respiratory Review, 2021, 30, 200340.	7.1	18
360	Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs, 2021, 81, 575-586.	10.9	51
361	Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmunity Reviews, 2021, 20, 102755.	5.8	28
362	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. Pharmaceuticals, 2021, 14, 251.	3.8	2
363	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. Journal of Clinical Medicine, 2021, 10, 1330.	2.4	11
364	Surgical Debulking for Symptomatic Management of Calcinosis Cutis of the Hand and Upper Extremity in Systemic Sclerosis. Journal of Hand Surgery, 2021, 46, 928.e1-928.e9.	1.6	5
365	18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Research and Therapy, 2021, 23, 76.	3.5	20
366	Treatment for systemic sclerosis-associated interstitial lung disease. Current Opinion in Rheumatology, 2021, 33, 240-248.	4.3	27
367	Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. Arthritis Care and Research, 2022, 74, 1575-1584.	3.4	13
368	Self-management interventions in systemic sclerosis: A systematic review. Research in Nursing and Health, 2021, 44, 376-392.	1.6	1
369	C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Modern Rheumatology, 2022, 32, 141-148.	1.8	3

#	ARTICLE	IF	CITATIONS
370	Raynaud's Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care. Deutsches A&#x0308;rztblatt International, 2021, 118, .	0.9	8
371	Cardiopulmonary Exercise Testing Is an Accurate Tool for the Diagnosis of Pulmonary Arterial Hypertension in Scleroderma Related Diseases. Pharmaceuticals, 2021, 14, 342.	3.8	4
372	Autologous stem cell transplantation in scleroderma. Presse Medicale, 2021, 50, 104065.	1.9	10
374	Digital Ulcers in Systemic Sclerosis. Presse Medicale, 2021, 50, 104064.	1.9	14
375	Scleroderma renal crisis. Presse Medicale, 2021, 50, 104063.	1.9	15
377	Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. Journal of Rheumatology, 2021, 48, 1427-1434.	2.0	4
378	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. JAMA Dermatology, 2021, 157, 851-858.	4.1	12
379	SARS-COV-2 vaccination after stem cell transplantation for scleroderma. Annals of the Rheumatic Diseases, 2021, 80, 1354-1355.	0.9	8
380	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplantation, 2021, 56, 1493-1508.	2.4	27
381	Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respiratory Research, 2021, 22, 162.	3.6	31
382	Emerging treatments for scleroderma/systemic sclerosis. Faculty Reviews, 2021, 10, 43.	3.9	11
383	Prevalence of Oral and Maxillofacial Disorders in Patients with Systemic Sclerosis: A Systematic Review. International Journal of Environmental Research and Public Health, 2021, 18, 5238.	2.6	12
384	Prediction and primary prevention of major vascular complications in systemic sclerosis. European Journal of Internal Medicine, 2021, 87, 51-58.	2.2	9
385	Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact. Diagnostics, 2021, 11, 911.	2.6	16
386	Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score. Bone Marrow Transplantation, 2021, 56, 2259-2267.	2.4	7
387	A preliminary study of possible fibrotic role of meprin metalloproteases in scleroderma patients. Archives of Rheumatology, 2021, 36, 510-517.	0.9	0
388	Stem cell therapy in dermatology. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 753-767.	0.6	11
389	Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis. Archivum Immunologiae Et Therapiae Experimentalis, 2021, 69, 17.	2.3	1

#	ARTICLE	IF	CITATIONS
390	An update on targeted therapies in systemic sclerosis based on a systematic review from the last 36 years. Arthritis Research and Therapy, 2021, 23, 155.	3.5	42
391	Simplified guidelines for the management of systemic sclerosis. , 0, 1, 24.		0
392	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2022, 7, 57-61.	1.7	7
393	Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Clinical Rheumatology, 2021, 40, 3185-3193.	2.2	10
394	Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. Journal of Personalized Medicine, 2021, 11, 600.	2.5	4
395	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 607-617.	3.4	3
396	Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cellular and Molecular Life Sciences, 2021, 78, 5527-5542.	5.4	22
397	The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis. Orphanet Journal of Rare Diseases, 2021, 16, 326.	2.7	2
398	Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis. Rheumatology, 2022, 61, 1476-1486.	1.9	7
399	Tratamiento con oxígeno hiperbárico en el fenómeno de Raynaud y las úlceras digitales asociadas a esclerosis sistémicas. Reumatología Clínica, 2022, 18, 246-248.	0.5	1
400	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod. Arthritis Research and Therapy, 2021, 23, 204.	3.5	8
401	The effectiveness of rotating versus single course antibiotics for small intestinal bacterial overgrowth. United European Gastroenterology Journal, 2021, 9, 645-654.	3.8	15
402	Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology, 2022, 61, 1936-1947.	1.9	15
403	Intravenous infusion of mesenchymal stem cells for refractory systemic sclerosis management: Two-year follow-up. Revista Colombiana De Reumatología, 2022, 29, 409-416.	0.1	1
404	Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatology International, 2021, 41, 1743-1753.	3.0	24
405	Patient's experiences of the barriers and facilitators to Methotrexate. Musculoskeletal Care, 2022, 20, 158-166.	1.4	6
406	Effect of monthly cyclophosphamide pulses on skin sclerosis in systemic sclerosis. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 728-731.	0.6	1
407	Distinct Metalloproteinase Expression and Functions in Systemic Sclerosis and Fibrosis: What We Know and the Potential for Intervention. Frontiers in Physiology, 2021, 12, 727451.	2.8	15

#	ARTICLE	IF	CITATIONS
408	Gastrointestinal manifestations of systemic sclerosis: An updated review. World Journal of Clinical Cases, 2021, 9, 6201-6217.	0.8	10
409	Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. Frontiers in Medicine, 2021, 8, 699532.	2.6	5
410	Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience. Journal of Rheumatology, 2022, 49, 68-73.	2.0	6
411	Systemic sclerosis-associated pulmonary arterial hypertension in children. Cardiovascular Diagnosis and Therapy, 2021, 11, 1137-1143.	1.7	6
413	Raynaud's phenomenon and digital ulcers: advances in evaluation and management. Current Opinion in Rheumatology, 2021, 33, 453-462.	4.3	9
414	Systemic Sclerosis and the Liver. Clinical Liver Disease, 2021, 18, 76-80.	2.1	2
415	Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort. Clinical Rheumatology, 2022, 41, 869-876.	2.2	5
416	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opinion on Drug Safety, 2022, 21, 311-333.	2.4	1
417	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. Rheumatic Disease Clinics of North America, 2021, 47, 757-780.	1.9	5
418	Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment. Arthritis Care and Research, 2021, , .	3.4	2
420	Review for best practice in clinical rheumatology juvenile systemic sclerosis “ Updates and practice points. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101688.	3.3	6
421	A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101666.	3.3	11
422	Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study. Journal of Scleroderma and Related Disorders, 2022, 7, 239719832110433.	1.7	1
423	Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101672.	3.3	1
424	Impact of Three Different Algorithms for the Screening of SSc-PAH and Comparison with the Decisions of a Multidisciplinary Team. Diagnostics, 2021, 11, 1738.	2.6	7
425	Scleroderma renal crisis: Case reports and update on critical issues. , 2021, 8, 162-167.		7
426	Systemic sclerosis related interstitial lung disease: What is the recommended treatment?. ReumatologĀa ClĀnica, 2021, 17, 490.	0.5	0
427	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs in Context, 2021, 10, 1-13.	2.2	5



#	ARTICLE	IF	CITATIONS
428	Opening the black box of non-pharmacological care in systemic sclerosis: a cross-sectional online survey of Dutch health professionals. <i>Rheumatology International</i> , 2021, 41, 1299-1310.	3.0	2
429	Treatment efficacy in secondary Raynaud's phenomenon. <i>Lancet Rheumatology, The</i> , 2020, 2, e132.	3.9	1
430	Electrocardiographic markers for the prediction of ventricular arrhythmias in patients with systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 478-486.	1.9	12
431	Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224829.	0.5	6
432	CD47 prevents the elimination of diseased fibroblasts in scleroderma. <i>JCI Insight</i> , 2020, 5, .	5.0	25
433	Why is a paediatric respiratory specialist integral to the paediatric rheumatology clinic?. <i>Breathe</i> , 2020, 16, 200212.	1.3	1
434	Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 57, 265-273.	1.0	11
435	The role of autoantibodies in the early diagnosis of systemic immunoinflammatory rheumatic diseases. <i>Sovremennaya Revmatologiya</i> , 2019, 13, 5-10.	0.5	4
436	Metabolic Targets for Treatment of Autoimmune Diseases. <i>Immunometabolism</i> , 2020, 2, .	1.6	34
437	Late Onset Nephrogenic Systemic Fibrosis in a Patient with Stage 3 Chronic Kidney Disease: a Case Report. <i>Journal of Korean Medical Science</i> , 2020, 35, e293.	2.5	3
438	A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1739-1746.	1.8	5
439	Phosphodiesterase-5 inhibitors: Raynaud's and beyond. <i>Indian Journal of Rheumatology</i> , 2017, 12, 227.	0.4	1
440	The burning question: To use or not to use cyclophosphamide in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2020, 7, 237-241.	0.6	7
441	Putative functional pathogenic autoantibodies in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2020, 7, 181-186.	0.6	8
442	Renal Involvement in Systemic Sclerosis. , 0, , .		2
443	Diffused Alveolar Hemorrhage in the Setting of Scleroderma Renal Crisis. <i>Cureus</i> , 2019, 11, e4932.	0.5	2
444	Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication. <i>Rheumatology International</i> , 2021, , 1.	3.0	2
445	Pharmacokinetics and Metabolism of Ziritaxestat (CLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 246-256.	1.6	8



#	ARTICLE	IF	CITATIONS
446	A Machine Learning Application to Predict Early Lung Involvement in Scleroderma: A Feasibility Evaluation. <i>Diagnostics</i> , 2021, 11, 1880.	2.6	14
447	Systemic sclerosis related interstitial lung disease: What is the recommended treatment?. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2021, 17, 490.	0.3	0
448	Combining systemic and locally applied cellular therapies for the treatment of systemic sclerosis. <i>Bone Marrow Transplantation</i> , 2022, 57, 17-22.	2.4	5
449	Acute Renal Failure during Progressive Systemic Sclerosis in the Regional University Teaching Hospital of Brest-La Cavale Blanche (France). <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2017, 07, 158-166.	0.2	0
450	III. The Particularity of CTD-PH Management. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2018, 107, 214-218.	0.0	0
451	Systemic sclerosis in 2017. <i>Vnitřni Lekarství</i> , 2018, 64, 146-154.	0.2	1
452	FRI0469Ā...Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a single centre pragmatic non-randomised trial. , 2018, , .		0
454	Systemic scleroderma treatment algorithms with the predominant skin and joint lesions, RaynaudĀ™s syndrome and digital ulcers according to modern guidelines. <i>BolĒ1, Sustavy, PozvonoĀnik</i> , 2018, 8, 150-158.	0.1	1
455	Therapy for digital ulcers in patients with systemic scleroderma. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 56, 777-781.	1.0	1
456	Algorithms of systemic scleroderma treatment with the predominant heart lesion, pulmonary arterial hypertension and interstitial lung disease according to modern guidelines. <i>Hypertension</i> , 2019, .	0.2	0
457	Gastrointestinal involvement in systemic sclerosis: diagnostic and therapeutic aspects. <i>Modern Gastroenterology</i> , 2019, .	0.1	1
458	ENDOTHELIAL DYSFUNCTION AND NEUROHUMORAL REGULATION OF BLOOD PRESSURE IN PATIENTS WITH SYSTEMIC SCLEROSIS. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019, 57, 445-451.	1.0	0
459	Systemic Sclerosis (Scleroderma). , 2020, , 263-275.		0
460	Edema of Hands and Hypopigmented Lesions on Her Neck and Cheeks. , 2020, , 97-102.		0
461	Pulmonary involvement in systemic sclerosis. , 2019, , 90-105.		0
463	Differing commissioning arrangements may contribute to geographic variation in clinical management of digital ulcers in systemic sclerosis. <i>Clinical Medicine</i> , 2020, 20, 343-345.	1.9	1
465	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. <i>Autoimmunity Reviews</i> , 2021, 20, 102978.	5.8	17
466	Treatment of systemic sclerosis. <i>Presse Medicale</i> , 2021, 50, 104088.	1.9	10

#	ARTICLE	IF	CITATIONS
467	The "Connective Tissue Diseases", 2022, , 357-420.		0
469	Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1539-1547.	0.9	10
470	Clinical Management of Tenosynovitis and Tendon Friction Rubs in Systemic Sclerosis. In Clinical Practice, 2021, , 373-379.	0.0	0
471	Practical Approach to Malnutrition and Weight Loss in SSc. In Clinical Practice, 2021, , 243-254.	0.0	0
473	Raynaud's Phenomenon. In Clinical Practice, 2021, , 67-77.	0.0	0
474	Critical Ischemia. In Clinical Practice, 2021, , 79-99.	0.0	0
475	Gut microbiome in systemic sclerosis: a potential therapeutic target. Postepy Dermatologii i Alergologii, 2022, 39, 101-109.	0.9	3
476	Rituximab Utilization Evaluation with Focused on Available Evidence for Off-Label Indications. Journal of Pharmaceutical Care, 0, , .	0.0	0
477	Systemic Sclerosis in the Elderly. , 2020, , 207-228.		0
478	Damage index changes in patients with systemic sclerosis: a retrospective analysis over a five-year period. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 42-47.	1.0	0
479	Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers. Annals of Medicine and Surgery, 2021, 71, 102984.	1.1	11
480	Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis. Journal of Blood Medicine, 2021, Volume 12, 951-964.	1.7	5
481	Nintedanib in treating interstitial lung disease associated with systemic scleroderma. Klinicka Farmakologie A Farmacie, 2021, 35, 80-86.	0.2	0
483	Treatment of Systemic Sclerosis Associated Interstitial Lung Disease. Journal of Clinical Rheumatology and Immunology, 2020, 20, 56-64.	0.4	1
484	Interstitial lung disease: course report. Breathe, 2020, 16, 200075.	1.3	0
485	Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 1. Clinical aspects. Sovremennaya Revmatologiya, 2020, 14, 91-97.	0.5	1
486	Economic burden of systemic sclerosis: systematic review. Farmakoekonomika, 2020, 13, 291-303.	1.2	2
487	Current therapy of interstitial pneumonia associated with systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 520-531.	1.0	4

#	ARTICLE	IF	CITATIONS
488	Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 175-182.	0.8	3
489	Non-invasive digital thermal monitoring and flow-mediated dilation in systemic sclerosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 97-101.	0.8	5
490	Effects of Polyurethane Foam Dressings as an Add-on Therapy in the Management of Digital Ulcers in Scleroderma Patients. Translational Medicine @ UniSa, 2020, 22, 10-14.	0.5	1
492	Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021002.	0.2	1
493	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 61-71.	1.7	14
494	MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy. International Journal of Molecular Sciences, 2021, 22, 12416.	4.1	9
495	Diet in Scleroderma: Is There a Need for Intervention?. Diagnostics, 2021, 11, 2118.	2.6	6
496	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. International Journal of Molecular Sciences, 2021, 22, 12681.	4.1	9
497	Changes in Plasma Phospholipid Metabolism Are Associated with Clinical Manifestations of Systemic Sclerosis. Diagnostics, 2021, 11, 2116.	2.6	4
498	Use of Mycophenolate Mofetil for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. Modern Rheumatology, 2021, , .	1.8	1
499	Serotonin and Systemic sclerosis. An emerging player in pathogenesis. Joint Bone Spine, 2021, 89, 105309.	1.6	3
500	Systemic sclerosis: clinical features and management. Medicine, 2021, , .	0.4	0
501	Indications for fertility preservation not included in the 2017 Japan Society of Clinical Oncology Guideline for Fertility Preservation in Pediatric, Adolescent, and Young Adult Patients treated with gonadal toxicity, including benign diseases. International Journal of Clinical Oncology, 2022, 27, 301-309.	2.2	4
503	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). Lancet Rheumatology, The, 2021, 3, e834-e843.	3.9	42
504	SYSTEMIC SCLERODERMIA. LITERATURE REVIEW. Bulletin of Problems Biology and Medicine, 2021, 4, 29.	0.1	0
505	Scleroderma nephropathy: unsolved problems. Juvenis Scientia, 2021, 7, 5-18.	0.2	0
506	Esomeprazole alleviates fibrosis in systemic sclerosis by modulating AhR/Smad2/3 signaling. Pharmacological Research, 2022, 176, 106057.	7.1	9
507	Choosing pharmacotherapy for ILD in patients with connective tissue disease. Breathe, 2021, 17, 210114.	1.3	1

#	ARTICLE	IF	CITATIONS
508	The Levels of Serum Serotonin Can Be Related to Skin and Pulmonary Manifestations of Systemic Sclerosis. <i>Medicina (Lithuania)</i> , 2022, 58, 161.	2.0	1
509	Current State and Issues of Regenerative Medicine for Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2022, 9, 813952.	2.6	3
510	Dysregulation of the gene signature of effector regulatory T cells in the early phase of systemic sclerosis. <i>Rheumatology</i> , 2022, , .	1.9	3
511	The Downregulation of PTGS2 Mediated by ncRNAs is Tightly Correlated with Systemic Sclerosis-Interstitial Lung Disease. <i>Frontiers in Genetics</i> , 2021, 12, 795034.	2.3	2
512	Mesenchymal Stem Cellâ€‘Based Therapy as a New Approach for the Treatment of Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, , 1.	6.5	15
514	Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patientsâ€‘High Efficacy of Rituximab. <i>Frontiers in Immunology</i> , 2021, 12, 817893.	4.8	6
515	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 168-178.	1.7	9
516	Systemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches. <i>Biomedicines</i> , 2022, 10, 163.	3.2	16
517	Microangiopathy in Inflammatory Diseasesâ€‘Strategies in Surgery of the Lower Extremity. <i>Life</i> , 2022, 12, 200.	2.4	1
519	Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. <i>Biomedicines</i> , 2022, 10, 316.	3.2	8
520	MSCs-laden injectable self-healing hydrogel for systemic sclerosis treatment. <i>Bioactive Materials</i> , 2022, 17, 369-378.	15.6	14
521	Involvement of the Nervous System in Systemic Sclerosis. <i>The Open Neurology Journal</i> , 2022, 16, .	0.4	0
522	Systemic sclerosis in adults. Part II: management and therapeutics. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 957-978.	1.2	7
523	Involvement of the Nervous System in Systemic Sclerosis. <i>The Open Neurology Journal</i> , 2022, 16, .	0.4	0
524	Successful Endovascular Therapy for Total Occlusion of the Distal Radial and Ulnar Artery with Palmar Artery Lesion in a Patient with Critical Hand Ischemia Associated with Systemic Sclerosis. <i>Vascular and Endovascular Surgery</i> , 2022, , 153857442110374.	0.7	0
525	Iontophoresis of treprostinil promotes wound healing in a murine model of scleroderma-related ulcers. <i>Rheumatology</i> , 2021, , .	1.9	1
526	Outcomes in patients with systemic sclerosis undergoing early <i>vs</i> delayed intervention with potential disease-modifying therapies. <i>Rheumatology</i> , 2022, 61, 3677-3685.	1.9	5
527	Autologous hematopoietic stem cell transplantation modifies specific aspects of systemic sclerosis-related microvasculopathy. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210848.	2.7	6

#	ARTICLE	IF	CITATIONS
528	Increased Complement Activation in Systemic Sclerosis Patients with Skin and Lung Fibrosis. Journal of Personalized Medicine, 2022, 12, 284.	2.5	4
529	Emerging Therapeutics in the Management of Connective Tissue Disease. Part II. Dermatomyositis and Scleroderma. Journal of the American Academy of Dermatology, 2022, , .	1.2	3
530	Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. Biomedicines, 2022, 10, 504.	3.2	2
531	Tocilizumab and its usage for skin diseases. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.2	3
532	Impaired Fibrinolysis Is Linked With Digital Vasculopathy and Onset of New Digital Ulcers in Systemic Sclerosis. Journal of Rheumatology, 2022, , jrheum.210931.	2.0	2
533	iNKT cells can effectively inhibit IL-6 production by B cells in systemic sclerosis. Cytotherapy, 2022, , .	0.7	1
534	Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox. Biomedicines, 2022, 10, 434.	3.2	5
535	Future Treatment Options in Systemic Sclerosisâ€”Potential Targets and Ongoing Clinical Trials. Journal of Clinical Medicine, 2022, 11, 1310.	2.4	9
536	Microvascular Imaging as a Novel Tool for the Assessment of Blood Flow Velocity in Patients with Systemic Sclerosis: A Single-Center Feasibility Study. Applied Sciences (Switzerland), 2022, 12, 2306.	2.5	4
537	Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis. Stem Cell Research and Therapy, 2022, 13, 118.	5.5	10
538	Management review of scleroderma renal crisis: An update with practical pointers. Modern Rheumatology, 2023, 33, 12-20.	1.8	3
539	Diastolic Function Assessment of Left and Right Ventricles by <scp>MRI</scp> in Systemic Sclerosis Patients. Journal of Magnetic Resonance Imaging, 2022, , .	3.4	1
540	Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis. Modern Rheumatology, 2023, 33, 330-337.	1.8	0
541	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	1.9	6
542	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Scientific Reports, 2022, 12, 5289.	3.3	6
543	Utility of phototherapy in patients with systemic sclerosis: Systematic review. Dermatologic Therapy, 2022, 35, e15478.	1.7	1
544	Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nature Reviews Rheumatology, 2022, 18, 276-285.	8.0	18
545	Autologous Haematopoietic Stem Cell Transplantation and Systemic Sclerosis: Focus on Interstitial Lung Disease. Cells, 2022, 11, 843.	4.1	1

#	ARTICLE	IF	CITATIONS
546	Angiotensin-converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 722-731.	1.5	2
547	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 472-489.	6.5	13
548	Rehabilitative interventions for ischaemic digital ulcers, pain, and hand functioning in systemic sclerosis: a prospective before-after study. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, 193.	1.9	2
549	Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases. <i>Advances in Therapy</i> , 2022, 39, 2222-2235.	2.9	9
550	PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3904.	4.1	13
551	An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. <i>Diagnostics</i> , 2022, 12, 616.	2.6	16
552	Molecular Effects of Auto-Antibodies on Angiotensin II Type 1 Receptor Signaling and Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3984.	4.1	5
553	Therapeutic effect of cyclin-dependent kinase 4/6 inhibitor on dermal fibrosis in murine models of systemic sclerosis. <i>Arthritis and Rheumatology</i> , 2021, , .	5.6	2
554	Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen. <i>Reumatologia Clínica (English Edition)</i> , 2021, , .	0.3	1
555	Efficacy of local oxygen-ozone therapy for the treatment of digital ulcer refractory to medical therapy in systemic sclerosis: A randomized controlled study. <i>Modern Rheumatology</i> , 2022, 32, 1102-1107.	1.8	4
556	Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies. <i>Frontiers in Medicine</i> , 2021, 8, 788250.	2.6	25
557	Lipid Alterations in Systemic Sclerosis. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 761721.	3.5	6
558	The economic burden of systemic sclerosis—A systematic review. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 110-120.	1.9	4
559	Study Protocol: A Randomized Controlled Prospective Single-Center Feasibility Study of Rheopheresis for Raynaud's Syndrome and Digital Ulcers in Systemic Sclerosis (RHEACT Study). <i>Frontiers in Medicine</i> , 2022, 9, 871744.	2.6	1
560	Management of scleroderma gastrointestinal disease: Lights and shadows. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 85-97.	1.7	4
561	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	2.7	6
562	Systemic Scleroderma—Definition, Clinical Picture and Laboratory Diagnostics. <i>Journal of Clinical Medicine</i> , 2022, 11, 2299.	2.4	15
569	Effects of fibromyalgia syndrome in patients with diffuse systemic sclerosis: Evaluation with 2010 American college of rheumatology criteria set. <i>Indian Journal of Rheumatology</i> , 2022, 17, 129.	0.4	0

#	ARTICLE	IF	CITATIONS
570	Raynaud's Phenomenon with Focus on Systemic Sclerosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2490.	2.4	8
571	Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2022, 24, 166-173.	4.7	8
572	Drugs Recommended in Adult Rheumatic Diseases, But Considered for Off-Label Use in Argentina. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 286-292.	0.3	0
573	Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 755-768.	1.9	6
574	Assessing the diagnostic value of a potential screening tool for detecting early interstitial lung disease at the onset of inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2022, 24, 107.	3.5	8
575	Management of Juvenile-Onset Systemic Sclerosis with Systemic Immunosuppressive Therapies: An Evidence-Based Review. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	0
576	Esclerosis sistémica inducida por paclitaxel. <i>Revista Española De Casos Clínicos En Medicina Interna</i> , 2022, 3, 52-55.	0.0	0
577	Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2022, 57, 1055-1062.	2.4	16
579	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	2.4	119
580	Calcineurin inhibitors in systemic sclerosis – a systematic literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210923.	2.7	1
581	The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
582	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis. <i>Clinical Rheumatology</i> , 2022, 41, 2755-2763.	2.2	6
583	Digital Gangrene in Systemic Sclerosis Patients: Not Only Due to the Microvascular Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
585	Letter to the Editor Regarding Esophageal Dysfunction and Systemic Sclerosis: Drugs Should be Kept in Mind. <i>Rheumatology and Therapy</i> , 0, , .	2.3	0
586	To choose or not? The value of discrete-choice experiments in rheumatology. <i>Nature Reviews Rheumatology</i> , 0, , .	8.0	0
587	Application of Integrated Traditional Chinese and Western Medicine in Treatment of Systemic Sclerosis: A Case Report. <i>Explore: the Journal of Science and Healing</i> , 2022, , .	1.0	0
588	Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. <i>Rheumatology</i> , 2023, 62, SI32-SI42.	1.9	4
589	Challenging diagnosis of renal failure associated with severe neurological symptoms in a patient with mixed connective tissue disease. <i>Journal of Scleroderma and Related Disorders</i> , 0, , 239719832210998.	1.7	0



#	ARTICLE	IF	CITATIONS
590	Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	10
591	Paradoxical Raynaud's phenomenon following iloprost infusion in a patient with systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 0, , 1-2.	1.1	1
592	JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	16
593	<scp>YouTube</scp> as a source of information on systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 887-892.	1.9	7
594	Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications. , 2022, , 229-255.		0
595	A comprehensive review of immunosuppressive drugs in pediatric dermatoses: Part II " methotrexate and mycophenolate mofetil. <i>Indian Journal of Paediatric Dermatology</i> , 2022, 23, 204.	0.1	0
596	Effect of vasodilator and immunosuppressive therapy on the endothelial dysfunction in patients with systemic sclerosis. <i>Clinical and Experimental Medicine</i> , 0, , .	3.6	2
597	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	51
598	Non-Classical HLA Determinants of the Clinical Response after Autologous Stem Cell Transplantation for Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7223.	4.1	1
599	Altered ocular microvasculature in patients with systemic sclerosis and very early disease of systemic sclerosis using optical coherence tomography angiography. <i>Scientific Reports</i> , 2022, 12, .	3.3	6
600	Toward Molecular Stratification and Precision Medicine in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	2
601	Clinical characteristics and outcomes of digital gangrene in connective tissue disorders: a longitudinal single-centre experience from Jodhpur, India. <i>Clinical Rheumatology</i> , 2022, 41, 3543-3549.	2.2	3
602	Sudden winter iloprost withdrawal in scleroderma patients during COVID-19 pandemic. <i>Microvascular Research</i> , 2022, , 104404.	2.5	1
603	Experience of successful autologous hematopoietic stem cell transplantation in patients with an unfavorable prognosis of systemic scleroderma. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 381-387.	1.0	0
604	Kidney Involvement in Systemic Sclerosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1123.	2.5	5
606	Assessment of disease outcome measures in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 527-541.	8.0	10
607	Kinetics of response to iloprost evaluated by laser speckle contrast analysis in systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 0, , 1-4.	1.1	2
608	Drugs associated with systemic sclerosis: An updated list of suspected drugs using the WHO pharmacovigilance database. <i>Autoimmunity Reviews</i> , 2022, 21, 103157.	5.8	0



#	ARTICLE	IF	CITATIONS
609	Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211164.	2.7	7
610	Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology, 0, , .	1.9	3
611	A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's. Rheumatology, 2023, 62, 824-828.	1.9	6
612	Long-Term Efficacy and Low Adverse Events of Methylprednisolone Pulses Combined to Low-Dose Glucocorticoids for Systemic Sclerosis: A Retrospective Clinical Study of 10 Years' Follow-Up. Journal of Inflammation Research, 0, Volume 15, 4421-4433.	3.5	4
613	Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis. Frontiers in Immunology, 0, 13, .	4.8	1
614	Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. PLoS ONE, 2022, 17, e0272327.	2.5	1
617	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND). PeerJ, 0, 10, e13471.	2.0	1
619	Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis. Rheumatology, 2023, 62, SI107-SI113.	1.9	1
620	Scleroderma cardiac crisis: A life-threatening but reversible complication of systemic sclerosis. Autoimmunity Reviews, 2022, 21, 103162.	5.8	4
621	Epidemiology and Treatment of Systemic Sclerosis in Korea. Journal of Rheumatic Diseases, 2022, 29, 200-214.	1.1	5
622	T cell abnormalities in systemic sclerosis. Autoimmunity Reviews, 2022, 21, 103185.	5.8	23
623	Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry. Biomedicines, 2022, 10, 2129.	3.2	5
624	Systemic Sclerosis Association with Malignancy. Clinical Reviews in Allergy and Immunology, 2022, 63, 398-416.	6.5	7
625	The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis. International Journal of Molecular Sciences, 2022, 23, 10150.	4.1	5
626	Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, <scp>Double-blind</scp>, <scp>Placebo-controlled</scp> Study. Arthritis and Rheumatology, 2023, 75, 459-467.	5.6	4
627	Fecal microbiome in systemic sclerosis, in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control. Journal of Scleroderma and Related Disorders, 2022, 7, 163-167.	1.7	0
628	The effect of rituximab on systemic sclerosis: A systematic review and meta-analysis. International Journal of Health Sciences, 0, , 4345-4364.	0.1	0
629	Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review. Journal of Scleroderma and Related Disorders, 0, , 239719832211241.	1.7	1

#	ARTICLE	IF	CITATIONS
630	Stem Cells as a Therapeutic Choice in Dermatological Disorders. Current Stem Cell Research and Therapy, 2023, 18, 1069-1075.	1.3	0
632	IV. Current Status and Prospects of Clinical Practice for Systemic Sclerosis. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2181-2188.	0.0	0
634	Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: Where do we stand? Volume II. Frontiers in Immunology, 0, 13, .	4.8	0
635	Esophageal Manifestations of Dermatological Diseases, Diagnosis, and Management. Current Treatment Options in Gastroenterology, 0, , .	0.8	0
636	Cellular-Based Therapies in Systemic Sclerosis: From Hematopoietic Stem Cell Transplant to Innovative Approaches. Cells, 2022, 11, 3346.	4.1	4
637	Plasma and Urine Levels of Glycosaminoglycans in Patients with Systemic Sclerosis and Their Relationship to Selected Interleukins and Marker of Early Kidney Injury. Journal of Clinical Medicine, 2022, 11, 6354.	2.4	1
638	Skin disorders and interstitial lung disease: Part IIâ€”The spectrum of cutaneous diseases with lung disease association. Journal of the American Academy of Dermatology, 2023, 88, 767-782.	1.2	2
639	Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open, 2022, 8, e002477.	3.8	7
640	Heart disease in the course of systemic sclerosis â€” an observational study. Reumatologia, 2022, 60, 318-325.	1.1	0
642	Pathogenetic rationale for prescribing menopausal hormone therapy for systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 538-545.	1.0	0
643	Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya, 2022, 60, 603-608.	1.0	0
644	Immune cellÂdysregulation as a mediator ofÂfibrosis in systemic sclerosis. Nature Reviews Rheumatology, 2022, 18, 683-693.	8.0	18
646	Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies. Journal of Clinical Medicine, 2022, 11, 6665.	2.4	3
647	Therapeutic potential of mesenchymal stem cells for refractory inflammatory and immune skin diseases. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
648	Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2023, 11, 45-54.	10.7	73
649	Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis. Seminars in Arthritis and Rheumatism, 2023, 58, 152136.	3.4	7
650	Improving outcomes in scleroderma: recent progress of cell-based therapies. Rheumatology, 2023, 62, 2060-2069.	1.9	2
651	Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine (United States), 2022, 101, e31780.	1.0	6

#	ARTICLE	IF	CITATIONS
652	Secular Trends in Systemic Sclerosis Mortality in the United States from 1981 to 2020. International Journal of Environmental Research and Public Health, 2022, 19, 15088.	2.6	0
653	Disease specific determinants of cardiopulmonary fitness in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2023, 58, 152137.	3.4	1
654	Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease. Journal of Translational Autoimmunity, 2022, 5, 100174.	4.0	2
655	Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2211371.	2.7	5
656	Advances in the Treatment of Systemic Sclerosis. , 2022, 1, 61.		0
657	Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort. RMD Open, 2022, 8, e002476.	3.8	2
658	Rapid and Sustained Effect of Ozone Major Autohemotherapy for Raynaud and Hand Edema in Systemic Sclerosis Patient: A Case Report. Cureus, 2022, , .	0.5	3
659	Decreased Pulse Wave Velocity in a Systemic Sclerosis Population: Preliminary Results from a Cross-Sectional Study. Journal of Personalized Medicine, 2022, 12, 1952.	2.5	0
660	Autologous hematopoietic stem cell transplantation improves long-term survivalâ€”data from a national registry. Arthritis Research and Therapy, 2022, 24, .	3.5	1
661	Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial. Trials, 2022, 23, .	1.6	2
663	Hematopoietic Cell Transplantation for Systemic Sclerosisâ€”A Review. Cells, 2022, 11, 3912.	4.1	2
664	Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study. Rheumatology, 2023, 62, 2550-2555.	1.9	4
665	Development of a Diagnostic Model Focusing on Esophageal Dysmotility in Patients with Systemic Sclerosis. Diagnostics, 2022, 12, 3142.	2.6	0
667	Specific Autoantibodies and Microvascular Damage Progression Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: Are There Peculiar Associations? An Update. Antibodies, 2023, 12, 3.	2.5	3
668	Patient Assessment Chronic Illness Care (PACIC) and its associations with quality of life among Swiss patients with systemic sclerosis: a mixed methods study. Orphanet Journal of Rare Diseases, 2023, 18, .	2.7	2
669	Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respiratory Research, 2023, 24, .	3.6	40
670	Diagnosing lung involvement in inflammatory rheumatic diseasesâ€”Where do we currently stand?. Frontiers in Medicine, 0, 9, .	2.6	2
671	A Phase II randomised controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 0, , .	1.9	0

#	ARTICLE	IF	CITATIONS
672	Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry. <i>Journal of Scleroderma and Related Disorders</i> , 0, , 239719832211457.	1.7	0
673	The prognostic role of the echocardiographic tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/sPAP) ratio and its relationship with NT-proANP plasma level in systemic sclerosis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	1
674	Cyclophosphamide Pulse Therapy in the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease: An Observational Study. <i>The Indian Journal of Chest Diseases &amp; Allied Sciences</i> , 2023, 64, 263-268.	0.1	0
676	Kollagenosen â€œ Begutachtung. <i>Springer Reference Medizin</i> , 2023, , 1-4.	0.0	0
677	Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
678	Challenges of aptamers as targeting ligands for anticancer therapies. , 2023, , 455-480.		0
679	Intravenous infusion of mesenchymal stem cells for refractory systemic sclerosis management: Two-year follow-up. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2022, 29, 409-416.	0.0	0
680	Management of systemic sclerosis: British Society for Rheumatology guideline scope. <i>Rheumatology Advances in Practice</i> , 2022, 7, .	0.7	4
681	Interstitial Lung Disease. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 279-293.	1.9	3
682	Gastrointestinal Tract Considerations Part I. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 295-318.	1.9	2
683	Juvenile and adult-onset scleroderma: Different clinical phenotypes. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 60, 152197.	3.4	3
684	Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth. <i>Clinical and Translational Gastroenterology</i> , 2023, 14, e00567.	2.5	5
685	Quality Measures in Systemic Sclerosis. <i>Diagnostics</i> , 2023, 13, 579.	2.6	0
686	Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
687	Research Progress on Clinical Characteristics of Interstitial Lung Disease Associated with Different Connective Tissue Diseases. <i>Advances in Clinical Medicine</i> , 2023, 13, 2006-2011.	0.0	0
688	Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 373-382.	1.2	3
689	Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease. <i>Annals of Medicine</i> , 2023, 55, 663-671.	3.8	4
690	Sistemik sklerozis tanÄ±lÄ± ve dijital Å¼4lser nedeniyle bosentan kullanan hastalarÄ±n retrospektif incelenmesi: On yÄ±llÄ±k tek merkez deneyimi. <i>UludaÄŸ Ėeniversitesi TÄ±p FakÅ¼ltesi Dergisi</i> , 0, , .	0.3	0

#	ARTICLE	IF	CITATIONS
691	Treatment of digital ulcers in systemic sclerosis: recent developments and future perspectives. <i>Clinical Rheumatology</i> , 0, , .	2.2	2
692	State-of-the-art evidence in the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2023, 19, 212-226.	8.0	21
693	MKP-1 Deficiency Exacerbates Skin Fibrosis in a Mouse Model of Scleroderma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4668.	4.1	1
695	Risk Factors for Respiratory Failure in Patients Hospitalized With Systemic Sclerosis: An Analysis of the National Inpatient Sample. <i>Cureus</i> , 2023, , .	0.5	1
696	COVID-19 infection after autologous stem cell transplantation for systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 0, , ard-2023-223915.	0.9	0
697	Raynaud's phenomenon: A brush up!. <i>Indian Dermatology Online Journal</i> , 2023, 14, 248.	0.5	1
698	Comment on: Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. <i>Rheumatology</i> , 0, , .	1.9	0
700	Cardiac involvement in systemic and local vasculitides: The value of non-invasive multimodality imaging. <i>Current Problems in Cardiology</i> , 2023, , 101718.	2.4	2
701	Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 0, , jrheum.221113.	2.0	0
702	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice â€œ Evidenceâ€Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	1.3	81
703	Pharmacological management of systemic sclerosis associated interstitial lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 0, , 1-10.	1.8	0
704	Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study. <i>ReumatologÃa ClÃnica</i> , 2023, 19, 351-357.	0.5	2
705	Tumor necrosis factor-Î± inhibitor-related autoimmune disorders. <i>Autoimmunity Reviews</i> , 2023, 22, 103332.	5.8	8
707	Traditional Chinese Medicine Integrated Responsive Microneedles for Systemic Sclerosis Treatment. <i>Research</i> , 2023, 6, .	5.7	3
708	Systemic sclerosis associated interstitial lung disease: a survey of current practices in France. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2023, 15, 1759720X2311597.	2.7	1
709	Management of Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: A Focus on the Role of the Pharmacist. <i>Integrated Pharmacy Research &amp; Practice</i> , 0, Volume 12, 101-112.	1.5	0
710	Systemic Sclerosis Quality of Life Questionnaire (SScQoL): translation into Turkish and assessing its psychometric properties. <i>Clinical Rheumatology</i> , 0, , .	2.2	0
711	Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease. <i>Scientific Reports</i> , 2023, 13, .	3.3	1

#	ARTICLE	IF	CITATIONS
712	Views of Exercise in People With Systemic Sclerosis: A Qualitative Study. <i>Bioengineered</i> , 2023, 12, 46-53.	3.2	0
713	Cold Hands or Feet. <i>Medical Clinics of North America</i> , 2023, 107, 829-844.	2.5	1
714	Pharmacological management of digital ulcers in systemic sclerosis - what is new?. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 1159-1170.	1.8	0
715	Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. <i>Rheumatology</i> , 0, , .	1.9	0
716	Systemic inflammatory diseases with lung involvement. , 2023, , 237-253.		0
717	Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 65, 86-100.	6.5	2
718	What is new in the treatment of interstitial lung diseases. <i>Pneumon</i> , 2023, 36, 1-9.	0.3	2
719	Sclerodermic hand: a retrospective study on the role of ultrasonography in the detection of subclinical joint involvement. <i>Clinical Rheumatology</i> , 0, , .	2.2	1
721	Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2023, 25, .	3.5	1
722	The Role of Autophagy and Apoptosis in Affected Skin and Lungs in Patients with Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11212.	4.1	0
723	Early initiation of angiotensin-converting enzyme inhibitor in patients with scleroderma renal crisis: a nationwide inpatient database study. <i>Rheumatology</i> , 0, , .	1.9	2
724	Immersion Ultrasound Therapy in Combination with Manual Therapy in the Treatment of Ischemic Digital Ulcers in Systemic Sclerosis. <i>Medicina (Lithuania)</i> , 2023, 59, 1335.	2.0	0
725	Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation. <i>Journal of Scleroderma and Related Disorders</i> , 2023, 8, 241-246.	1.7	1
726	Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis. <i>Pharmaceuticals</i> , 2023, 16, 1066.	3.8	0
727	Further insight into systemic sclerosis from the vasculopathy perspective. <i>Biomedicine and Pharmacotherapy</i> , 2023, 166, 115282.	5.6	2
729	Biomarkers in Systemic Sclerosis: An Overview. <i>Current Issues in Molecular Biology</i> , 2023, 45, 7775-7802.	2.4	0
730	Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
731	Endothelial Dysfunction in Systemic Sclerosis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14385.	4.1	3

#	ARTICLE	IF	CITATIONS
732	Treatable Traits in Systemic Sclerosis. Clinical Reviews in Allergy and Immunology, 2023, 65, 251-276.	6.5	3
733	Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?. Autoimmunity Reviews, 2023, , 103439.	5.8	2
734	Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study. Reumatología Clínica (English Edition), 2023, 19, 351-357.	0.3	0
735	Determinants of Depressive Symptoms, Quality of Life, Subjective Health Status and Physical Limitation in Patients with Systemic Sclerosis. Acta Dermato-Venereologica, 0, 103, adv6502.	1.3	2
736	Mode of action, indications and recommendations on extracorporeal photopheresis (ECP). JDDG - Journal of the German Society of Dermatology, 0, , .	0.8	0
738	The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosisâ€“Associated Interstitial Lung Disease. Journal of Clinical Medicine, 2023, 12, 6680.	2.4	0
739	Investigational drugs for the treatment of scleroderma: whatâ€™s new?. Expert Opinion on Investigational Drugs, 2023, 32, 601-614.	4.1	0
740	Solvent-Induced Raynaudâ€™s Phenomenon. Cureus, 2023, , .	0.5	0
741	Immunoglobulins in systemic sclerosis management. A large multicenter experience. Autoimmunity Reviews, 2023, 22, 103441.	5.8	2
742	Cardiac magnetic resonance assessment of cardiac involvement in autoimmune diseases. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
743	Distinct molecular subtypes of systemic sclerosis and gene signature with diagnostic capability. Frontiers in Immunology, 0, 14, .	4.8	0
744	Boosting Awareness of Sclerotic Skin Diseases: Exploring the Inflammatory Overlap of Sclerotic Skin Disease and <scp>COVID</scp>â€™19 Vaccination. Arthritis Care and Research, 2024, 76, 164-170.	3.4	0
745	Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis. Thorax, 2023, 78, 1188-1196.	5.6	2
747	Respiratory involvement in connective tissue diseases. European Journal of Internal Medicine, 2023, , .	2.2	2
748	Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis. Journal of Inflammation Research, 0, Volume 16, 4633-4660.	3.5	0
749	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial. Lancet Rheumatology, The, 2023, 5, e660-e669.	3.9	1
750	Systemic sclerosis interstitial lung disease: unmet needs and potential solutions. Nature Reviews Rheumatology, 0, , .	8.0	0
751	Treatment of Scleroderma-Related Microstomia Using Hyaluronic Acid: An Interventional Study. Life, 2023, 13, 2176.	2.4	1



#	ARTICLE	IF	CITATIONS
752	Wirkweise, Indikationen und Therapieempfehlungen der extrakorporalen Photopherese (ECP). JDDG - Journal of the German Society of Dermatology, 2023, 21, 1369-1381.	0.8	0
753	Antifibrotic effect of apremilast in systemic sclerosis dermal fibroblasts and bleomycin-induced mouse model. Scientific Reports, 2023, 13, .	3.3	0
754	The effect of calcium channel blockers on digital ulcers in systemic sclerosis: data from a prospective cohort study. Clinical Rheumatology, 0, , .	2.2	0
755	Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. The Cochrane Library, 2023, 2023, .	2.8	0
756	Juvenile Scleroderma. Indian Journal of Pediatrics, 0, , .	0.8	1
758	Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. RMD Open, 2023, 9, e003349.	3.8	0
759	Recent Advances in Treatment of Systemic Sclerosis and Morphea. American Journal of Clinical Dermatology, 2024, 25, 213-226.	6.7	0
760	Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists. Annals of Pharmacotherapy, 0, , .	1.9	0
761	Systemic sclerosis is a risk factor of incident psoriasis: results from a nationwide cohort study. Frontiers in Immunology, 0, 14, .	4.8	1
763	A Multinational Survey Investigating the Unmet Needs and Patient Perspectives Concerning Proton Pump Inhibitors in Systemic Sclerosis. Arthritis Care and Research, 0, , .	3.4	0
764	Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022. Expert Review of Clinical Immunology, 0, , 1-18.	3.0	0
765	French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases. Revue De Medecine Interne, 2024, 45, 79-99.	1.0	1
766	Nanomedicines for targeted pulmonary delivery: receptor-mediated strategy and alternatives. Nanoscale, 2024, 16, 2820-2833.	5.6	0
767	Serum levels of angiotensin converting enzyme 2 in patients with systemic sclerosis. Egyptian Rheumatologist, 2024, 46, 51-55.	1.0	0
768	Effective Management of Hypertensive Emergencies with Aliskiren Treatment in a Patient Before and After Introducing Hemodialysis Secondary to Scleroderma Renal Crisis-like Condition Under Corticosteroid Treatment for Sjögren Syndrome-associated Multiple Mononeuropathy. Internal Medicine, 2024, , .	0.7	0
769	Approval status of essential therapeutic drugs for systemic sclerosis versus that of drugs for rheumatoid arthritis. Journal of Scleroderma and Related Disorders, 2024, 9, 23-28.	1.7	0
770	Severe methotrexate toxicity in elderly patients under diuretics. RMD Open, 2024, 10, e003827.	3.8	1
771	Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study. Clinical Rheumatology, 2024, 43, 1073-1082.	2.2	0



#	ARTICLE	IF	CITATIONS
772	Practice pattern for the use of intravenous iloprost for the treatment of peripheral vasculopathy in systemic sclerosis: A caseâ€“control study from the Italian national multicenter â€œSPRINGâ€“ (Systemic) Tj ETQq0,0,0 rgBT /Overlock 138-49.	1.7	0
773	Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. RMD Open, 2024, 10, e003216.	3.8	0
776	Exploring the Utility of Circulating Endothelial Cell-Derived Extracellular Vesicles as Markers of Health and Damage of Vasal Endothelium in Systemic Sclerosis Patients Treated with Iloprost. Biomedicines, 2024, 12, 295.	3.2	0
777	A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's. Rheumatology, 0, , .	1.9	0
778	Systemic sclerosis associated respiratory involvement: Scopus-based analysis of articles in 2013â€“2022. Rheumatology International, 2024, 44, 693-702.	3.0	0
779	Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine, 2024, 69, 102476.	7.1	0
780	Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis. International Journal of Molecular Sciences, 2024, 25, 2299.	4.1	0
782	Digital gangrene in systemic sclerosis patients: not only due to the microvascular disease. Clinical Rheumatology, 2024, 43, 1083-1092.	2.2	0
783	Lung ultrasound is a promising screening tool to rule out interstitial lung disease in patients with rheumatoid arthritis. Respiriology, 0, , .	2.3	0
784	Platelet-rich plasma for the treatment of scleroderma-associated ulcers: a single-center experience and literature review. Dermatology Reports, 0, , .	0.8	0
785	A multi-national survey to identify cliniciansâ€™ perspectives concerning Proton Pump inhibitors in patients with systemic sclerosis. Seminars in Arthritis and Rheumatism, 2024, 67, 152419.	3.4	0
786	Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach. Expert Review of Clinical Immunology, 0, , 1-20.	3.0	0
787	Clinical course and factors associated with progressive acro-osteolysis in early systemic sclerosis: a retrospective cohort study. Scientific Reports, 2024, 14, .	3.3	0
788	SekundÃres Raynaud-PhÃnomen. Springer Reference Medizin, 2024, , 1-9.	0.0	0
789	Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 0, , .	2.4	0
790	Phenotypes of patients with systemic sclerosis in the Chinese Han population: a cluster analysis. Clinical Rheumatology, 2024, 43, 1635-1646.	2.2	0
791	Overlapping Case of Advanced Systemic Sclerosis and IgG4-Related Disease after Autologous Hematopoietic Stem Cell Transplantation. Medicina (Lithuania), 2024, 60, 496.	2.0	0
793	Vasoactive drugs for the treatment of pulmonary hypertension associated with interstitial lung diseases: a systematic review. BMJ Open Respiratory Research, 2024, 11, e002161.	3.0	0

#	ARTICLE	IF	CITATIONS
794	Juvenile Systemic Sclerosis: About 9 Cases. Open Journal of Pediatrics, 2024, 14, 320-326.	0.1	0